Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.59%
#2 Venom Venom +24.69%
#3 Decred Decred +10.82%
#4 DexNet DexNet +7.57%
#5 TRIA TRIA +6.91%
#6 Status Status +6.45%
#7 Wibx Wibx +5.98%
#8 SkyAI SkyAI +5.16%
#9 Talus Network Talus Network +4.56%
#10 Audiera Audiera +4.30%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Metacare Co., Ltd. Metacare Co., Ltd.

Metacare Co., Ltd.

118000
Rangering i aksjer #30588
Headquartered in Seoul, South Korea, Wooridul Huebrain Limited was founded in... Headquartered in Seoul, South Korea, Wooridul Huebrain Limited was founded in 2009. The company's operations span the medical, life and health, pharmaceutical, and storage industries. Its offerings include a range of medical equipment and devices, health-related apparatus, pharmaceutical products, and computer server solutions. The firm rebranded as Wooridul Huebrain Limited in April 2014, having previously operated under the name Wooridul Life Sciences Limited.
Aksjekurs
$0.94181426
Markedsverdi
$16.18M
Endring (1 dag)
-1.23%
Endring (1 år)
-58.24%
Land
KR
Handel Metacare Co., Ltd. (118000)

Kategori

Healthcare
P/S-forhold for Metacare Co., Ltd. (118000)
P/S-forhold per 2026 TTM: 0
Ifølge Metacare Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Metacare Co., Ltd. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
13.95 -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
6.41 -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
6.85 -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
4.66 -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
5.05 -
US